Advertisement

Clinical Pharmacokinetics

, Volume 58, Issue 3, pp 401–401 | Cite as

Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

  • Robert HermannEmail author
  • Mats O. Karlsson
  • Ana M. Novakovic
  • Nadia Terranova
  • Markus Fluck
  • Alain Munafo
Correction
  • 338 Downloads

1 Correction to: Clinical Pharmacokinetics  https://doi.org/10.1007/s40262-018-0695-9

Section 1, para 2, lines 2-4 which previously read:

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.

Should read:

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), primarily by deoxycytidine kinase.

Section 2.4, para 3, lines 4-6 which previously read:

Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated by 5ʹ-nucleotidase to Cd-ATP [10, 11].

Should read:

Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated to Cd-ATP [10, 11].

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Robert Hermann
    • 1
    Email author
  • Mats O. Karlsson
    • 2
  • Ana M. Novakovic
    • 3
  • Nadia Terranova
    • 4
  • Markus Fluck
    • 3
  • Alain Munafo
    • 4
  1. 1.Clinical Research Appliance (Cr Appliance)GelnhausenGermany
  2. 2.Department of Pharmaceutical BiosciencesUppsala UniversityUppsalaSweden
  3. 3.Merck KGaADarmstadtGermany
  4. 4.Merck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaADarmstadtGermany

Personalised recommendations